Concentration dependency of an acyl glucuronide metabolite in eltrombopag-induced hepatotoxicity: Role of UGT1A1 genotype

Eltrombopag acyl glucuronide metabolite — concentration-dependent toxicity modulated by UGT1A1 genotype

UGT1A1 genotype modulates eltrombopag-induced hepatotoxicity through accumulation of an acyl glucuronide metabolite. Eltrombopag is an oral thrombopoietin receptor agonist used in immune thrombocytopenia and aplastic anemia. This study characterizes the role of UGT1A1 genotype in eltrombopag hepatotoxicity through concentration-dependent acyl glucuronide metabolite accumulation. ⚠️ Summary written from title (RSS abstract unavailable — authors/PMID to verify via DOI).

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

UGT1A1 pharmacogenetics is already well-documented (irinotecan, UGT1A1*28). Its role in eltrombopag hepatotoxicity adds a clinically relevant drug-gene interaction for a niche but potentially serious hepatotoxic drug. Relevant for therapeutic monitoring discussions in eltrombopag-treated patients according to their UGT1A1 status.

Clinical impact : 2/3 · Evidence strength : 2/3 · Novelty : 2/2 · Sample size : 0/1 · Journal quality : 1/1 → Total : 7/10